Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2018 Aug 28;19(9):2548. doi: 10.3390/ijms19092548

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2018 by the authors.

Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).

PMC Copyright notice

Prognostic impact of FGFR3 and TP53 mutations on tumor progression in papillary non-invasive (pTa) tumors. Progression-free survival (PFS) is shown. (A) Univariate survival analysis illustrates that detected FGFR3 mutations (red curve, n = 14) predict shorter PFS compared to non-mutated FGFR3 gene status (blue curve, n = 15). (B) Kaplan–Meier analysis of tumors with mutated TP53 (red curve, n = 5) compared to wildtype TP53 (blue curve, n = 24). (C) Impact of double mutations on risk stratification of tumor progression is shown. Survival analysis of double mutations (red curve, n = 2) compared to all other combinations of mutated and non-mutated FGFR3 and TP53 genes (blue curve, n = 27) in pTa tumors. n: overall number of cases; events: overall events of tumor progression.